Cancer Chemotherapy and Pharmacology

Aims & Scope

Addressing a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels, Cancer Chemotherapy and Pharmacology is an eminent journal in the field.

The primary focus in this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials.

It is essential reading for pharmacologists and oncologists giving results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.3
2024	2.70

Journal Rank

Year	Value
2024	5088

Journal Citation Indicator

Year	Value
2024	1145

SJR (SCImago Journal Rank)

Year	Value
2024	0.969

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	127

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Determination of subcutaneous tumor size in athymic (nude) mice

  Citation: 1453

  Authors: Mary M., C. Patrick

• Platinum-based drugs: past, present and future

  Citation: 753

  Authors: Shahana, Ganna V.

• Matrix metalloproteinases and metastasis

  Citation: 547

  Authors: David E., William G.

• Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

  Citation: 523

  Authors: Johannes, Jim, Etienne, Brigitte, Ludger, Kazushige, Bruno, Masahiro, Erhard, Sarah

• Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats

  Citation: 493

  Authors: Izet M., Miguel, Zhihua, Thomas N., David L.

• Advances in ovarian cancer therapy

  Citation: 453

  Authors: Alexander J., Patrycja, Katarzyna A., Katarzyna M.

• A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

  Citation: 432

  Authors: Luis E., Kyriakos, Alejandro D., E. Gabriella, Robert S., Mark N., Caio M., James J., Khaled, Virginia K., Stewart, Donald T., Metin, Joseph, Theodore J.

• Ruthenium-based chemotherapeutics: are they ready for prime time?

  Citation: 427

  Authors: Emmanuel S., Ashkan

• Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent

  Citation: 413

  Authors: Jeffrey G., Robert L., Michael R., Louis

• Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

  Citation: 397

  Authors: Brett E., Carlo L., Bill, Lee S., George D., Robert J.

---